Sponsored
Jeplus.in
Purchase All Medicines.Get 10% Offer
Pharma Tech
FDA expands J&J’s Rybrevant Faspro label with head and neck cancer approval
The accelerated approval marks the first indication beyond lung cancer for J&J’s bispecific antibody.
Read Full Article
Pharma Tech
MHRA champions patient voices through new policyÂ
Through its PPIE initiative, the MHRA plans to consider a diverse range of patient and public opinions when making regulatory decisions.
Read Full Article
Pharma Tech
Armada to combine with Brains Bioceutical in $750m deal
Armada Acquisition has entered a definitive business combination agreement with Brains Bioceutical that values the latter at an implied pre-money equity value of $750m.
Read Full Article
Pharma Tech
Alfasigma receives EC’s expanded approval for filgotinib to treat axSpA
Alfasigma has received the EC's expanded approval for Jyseleca to treat adult patients living with active axial spondyloarthritis (axSpA).
Read Full Article
Pharma Tech
Cordavis to stay in CVS Health after bifurcation of $117bn empire
Cordavis was established by CVS Health three years ago to capture more of the US biosimilar supply chain.
Read Full Article
Sponsored content
Featured promotional
News
Latest stories
ET Pharma
Nov 7, 2026, 2:05 AM
GSK, Moderna settle patent dispute over Moderna COVID, RSV shots
GSK had sued Moderna in 2024 over lipid nanoparticle technology used in the vaccines to transport fragile messenger RNA (mRNA) into the human body
ET Pharma
Nov 7, 2026, 2:03 AM
Bayer to invest Rs 200 Crore in Karnataka; MoU signed
The company intends to perform the groundbreaking ceremony for the project before the Global Investors' Meet scheduled for April next year and is keen to commence manufacturing activities, Large and Medium Industries Minister M B Patil said.
Pharma Tech
Nov 6, 2026, 11:34 AM
FDA expands J&J’s Rybrevant Faspro label with head and neck cancer approval
The accelerated approval marks the first indication beyond lung cancer for J&J’s bispecific antibody.
PharmaShots
Nov 6, 2026, 11:08 AM
ANI Pharmaceuticals Announces ~$560M Recommended Cash Offer to Acquire Egetis Therapeutics
Shots: ANI Pharmaceuticals has announced a recommended public cash offer to acquire Egetis Therapeutics for SEK 11.25/share (27% premium to the 60-day VWAP), valuing the offer at ~SEK 5.6B (~$560M); EV ~$434M after adjusting for Egetis’ $190M Rare Pediatric Disease PRV sale Deal adds Emcitate (tiratricol), the first & only approved therapy in the US… The post ANI Pharmaceuticals Announces ~$560M Recommended Cash Offer to Acquire Egetis Therapeutics appeared first on PharmaShots.
PharmaShots
Nov 6, 2026, 11:07 AM
The US FDA Sets PDUFA Date of Apr 9, 2027 for Elevar’s Resubmitted Rivoceranib + Camrelizumab NDA in 1L uHCC
Shots: The US FDA has assigned a PDUFA target action date of Apr 9, 2027, for Elevar Therapeutics’ resubmitted NDA of rivoceranib + Hengrui Pharma’s resubmitted BLA of camrelizumab as 1L systemic therapy for unresectable or metastatic HCC Applications will be reviewed under an integrated process; the Oct 9, 2026, resubmissions respond to the FDA’s… The post The US FDA Sets PDUFA Date of Apr 9, 2027 for Elevar’s Resubmitted Rivoceranib + Camrelizumab NDA in 1L uHCC appeared first on PharmaShots.
PharmaShots
Nov 6, 2026, 11:05 AM
Theraclion’s Sonovein Receives the US FDA’s De Novo Authorization for Non-Invasive Treatment of GSV Reflux
Shots: The US FDA has granted De Novo marketing authorization (Nov 4, 2026) to Theraclion’s Sonovein for coagulation of blood vessels in pts with superficial venous reflux in Great Saphenous Vein (GSV) segments, establishing a new device classification Authorization was supported by the Pivotal (VEINRESET) study (n=70; 4 US & EU centers; NCT05926830), which met… The post Theraclion’s Sonovein Receives the US FDA’s De Novo Authorization for Non-Invasive Treatment of GSV Reflux appeared first on PharmaShots.
News
Latest industry coverage
Google News
Nov 8, 2026, 3:15 PM
Why Royalty Pharma Investors Could Be the Quiet Winners From Revolution Medicines' Groundbreaking Pancreatic Cancer Drug - The Motley Fool
Why Royalty Pharma Investors Could Be the Quiet Winners From Revolution Medicines' Groundbreaking Pancreatic Cancer Drug  The Motley Fool
Google News
Nov 8, 2026, 3:09 PM
Sun Pharma, Divi's Lab, Wockhardt: Pharma stocks surge up to 8% during Muhurat Trading session; why did stocks rally today? - Dailyhunt
Sun Pharma, Divi's Lab, Wockhardt: Pharma stocks surge up to 8% during Muhurat Trading session; why did stocks rally today?  Dailyhunt
Google News
Nov 8, 2026, 2:47 PM
Why global pharma is betting on India’s next-generation CDMOs | Hindustan Times - Hindustan Times
Why global pharma is betting on India’s next-generation CDMOs | Hindustan Times  Hindustan Times
Google News
Nov 8, 2026, 2:09 PM
SpyGlass Pharma (SGP) Stock Looks Pricey After Its 50% Monthly Jump - Yahoo Finance
SpyGlass Pharma (SGP) Stock Looks Pricey After Its 50% Monthly Jump  Yahoo Finance
Google News
Nov 8, 2026, 2:09 PM
Amgen’s Dividend Has Grown 800% Since 2011. Here’s What It Pays Today - 24/7 Wall St.
Amgen’s Dividend Has Grown 800% Since 2011. Here’s What It Pays Today  24/7 Wall St.
Google News
Nov 8, 2026, 1:39 PM
137 Anti-Cancer Drugs Under Price Controls; 1,031 Formulations Report Reductions Effective November 9 - www.nationpathindia.com
137 Anti-Cancer Drugs Under Price Controls; 1,031 Formulations Report Reductions Effective November 9Â Â www.nationpathindia.com
Google News
Nov 8, 2026, 1:13 PM
Drug Safety in India: Centre Proposes Immediate Licence Suspension for Medicines Failing Critical Quality Tests - www.nationpathindia.com
Drug Safety in India: Centre Proposes Immediate Licence Suspension for Medicines Failing Critical Quality Tests  www.nationpathindia.com
Google News
Nov 8, 2026, 11:48 AM
Supriya Lifescience Sales & Marketing GM Sreekant Sreedharan Granted Bail in NDPS Act Case - Medical Dialogues
Supriya Lifescience Sales & Marketing GM Sreekant Sreedharan Granted Bail in NDPS Act Case  Medical Dialogues
Google News
Nov 8, 2026, 11:36 AM
Gufic Biosciences Gets ITAT Relief as Rs 11.88 Crore Tax Dispute Sent Back for Fresh Assessment - Medical Dialogues
Gufic Biosciences Gets ITAT Relief as Rs 11.88 Crore Tax Dispute Sent Back for Fresh Assessment  Medical Dialogues
Sponsored placement
Featured promotions
Sponsored
Jeplus.in
Purchase All Medicines.Get 10% Offer